Acute Ischemic Stroke Trial - Oral Aspirin vs Intravenous Heparin on Stroke Progression "AIST"


Phase N/A Results N/A

Trial Description

To compare the effects of intravenous heparin with those of oral aspirin on acute ischemic stroke progression.


Trial Design

Multi-center, prospective, single-blinded, randomized, controlled study.

Patient Involvement

Eligible patients received a complete diagnostic workup for stroke, including MRI and MRA, and were randomized into either a heparin-treatment group or an aspirin-treatment group. The heparin group received intravenous heparin, titrated according to activated partial thromboplastin time (aPTT) for 6 days. At that point, the heparin was discontinued, and the patients received aspirin 300 mg/day for the rest of the study. Patients in the aspirin group received aspirin 300 mg/day throughout the study period. All patients had their NIHSS score evaluated daily for 1 week, and again at 2 weeks. MRS and BI scores were assessed at 1 and 3 months.


Type Measure Time Frame Safety Issue
Primary National Institute of Health Stroke Scale (NIHSS) score at 1 week, relative to baseline NIHSS score.
Secondary Barthel Index (BI) and Modified Rankin Scale (MRS) at 3 months.